• Decrease
• Increase

The Prostate Cancer Clinical Trials Consortium (PCCTC) is a 13-member clinical research group sponsored by the Prostate Cancer Foundation and the Department of Defense Prostate Cancer Research Program (PCRP) that offers simplified solutions for multicenter clinical trials. Capitalizing on their scientific and clinical expertise and unique institutional resources, PCCTC members collaborate to design, implement and complete phase I and phase II trials in prostate cancer to rapidly bring scientific discoveries to patients.

Latest News

Positive Results for Phase 3 MDV3100 Trial (11/03/11)

Positive results from early-phase PCCTC study led to successful phase III development.

Movember to “Change the Face” of Men’s Health (10/31/11)

Global initiative has raised more than $174 million to support vital cancer awareness and education, survivorship and research programs.

Tasquinimod Slows Progression, Improves Progression-Free Sur (10/26/11)

Results of PCCTC clinical trial published in the Journal of Clinical Oncology

Alpharadin Gains FDA Fast Track Designation (08/24/11)

Drug improves survival in patients with bone metastases resulting from castration-resistant prostate cancer (CRPC)